ArticlePulmonary circulation2022
A unique gut microbiota signature in pulmonary arterial hypertension: A pilot study.
Article in Pulmonary circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 20 citations in OpenAlex.
- Impact of Combined Botanical Functional Ingredients on the Canine Gut Microbiome.Veterinary sciences · 2026Article
- The bile acid-oxysterol axis in pulmonary arterial hypertension: from sterol trafficking to precision phenotyping and therapeutic opportunities.Molecular biology reports · 2026Review
- Lactobacillus Is Associated With Disease in Pulmonary Arterial Hypertension: A Prospective Cohort Study.Comprehensive physiology · 2026Article
- Gut microbiota and western dietary patterns associated with behavioral problems in children and adolescents: a cross-sectional study.Nutrition journal · 2026Article
- Reduction in microbiota-derived short-chain fatty acids contributes to the pathogenesis of pulmonary arterial hypertension.Respiratory research · 2026Article
- SCM-198 ameliorates pulmonary arterial hypertension by modulating gut microbiota in rats.Journal of thoracic disease · 2025Article
- Article
- Gut Microbiome in Pulmonary Arterial Hypertension-An Emerging Frontier.Infectious disease reports · 2025Review
- Cross-sectional study on ethnic variations in gut microbiome diversity and hypertension severity.Bioinformation · 2025Article
- Respiratory diseases and the gut microbiota: an updated review.Frontiers in cellular and infection microbiology · 2025Review
- Shaoyao Gancao decoction alleviates functional constipation by inhibitingFrontiers in cellular and infection microbiology · 2025Article
- Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension.American journal of physiology. Lung cellular and molecular physiology · 2024Review
- Aberrant long-chain fatty acid metabolism associated with evolving systemic sclerosis-associated pulmonary arterial hypertension.American journal of physiology. Lung cellular and molecular physiology · 2024Observational
- Alternations in the human skin, gut and vaginal microbiomes in perimenopausal or postmenopausal Vulvar lichen sclerosus.Scientific reports · 2024Article
- Promising dawn in the management of pulmonary hypertension: The mystery veil of gut microbiota.iMeta · 2024Review
- Pulmonary Hypertension and the Gut Microbiome.Biomedicines · 2024Review
- The Role of the Gallbladder, the Intestinal Barrier and the Gut Microbiota in the Development of Food Allergies and Other Disorders.International journal of molecular sciences · 2022Review
- The Role of Gut and Airway Microbiota in Pulmonary Arterial Hypertension.Frontiers in microbiology · 2022Review
- A unique gut microbiota signature in pulmonary arterial hypertension: A pilot study.Pulmonary circulation · 2022Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Pulmonary arterial hypertension (PAH) is a progressive, ultimately fatal cardiopulmonary disease associated with a number of physiologic changes, which is believed to result in imbalances in the intestinal microbiota. To date, comprehensive investigational analysis of the intestinal microbiota in human subjects is still limited. To address this, we performed a pilot study of the intestinal microbiome in 20 PAH and 20 non-PAH healthy control subjects, recruited from a single center, with each PAH subject recruited simultaneously with a cohabitating non-PAH control subject. Shotgun metagenomic sequencing was used to analyze the microbiome profiles. There were no differences between PAH and non-PAH subjects across several measures of microbial abundance and diversity (Alpha Diversity, Beta Diversity, F/B ratio). The relative abundance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.